Compound Detail
CHEMBL864
CARBINOXAMINE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL864 |
| Name | CARBINOXAMINE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | OJFSXZCBGQGRNV-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
3
Targets
3
Activities
3
Assay Types
0
PK Parameters
20
Publications
3
Known Names
1
Indications
Molecular Properties
290.8
MW (Da)
3.40
ALogP
3
HBA
0
HBD
25.4
PSA (Ų)
0.82
QED
0
Ro5 Violations
6
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1982 |
| Availability | Withdrawn |
| Chirality | Racemic |
Indications
Hypersensitivity
ATC Classification
R06AA08
carbinoxamine
Level 1: RESPIRATORY SYSTEM
Level 2: ANTIHISTAMINES FOR SYSTEMIC USE
Drug Warnings
Withdrawn
General Warning
High incidence of adverse drug reactions (ADRs) at therapeutic levels
Activity Summary
EC50 1 meas. best 6.6
IC50 1 meas. best 5.03
Ki 1 meas. best 5.97
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| NON-PROTEIN TARGET CHEMBL3879801 | EC50 | 6.6 | 6.6 | 250.0 | 1 |
| Voltage-gated L-type calcium channel CHEMBL2095177 | Ki | 5.97 | 5.97 | 1080.0 | 1 |
| Ileum CHEMBL613680 | IC50 | 5.03 | 5.03 | 9340.0 | 1 |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| NON-PROTEIN TARGET | EC50 | = | 250.0 | nM | 6.6 | Negative inotropic activity in guinea pig left atrium assessed as decrease in at... | 18754582 |
| Voltage-gated L-type calcium channel | Ki | = | 1080.0 | nM | 5.97 | Displacement of [3H]diltiazem from L-type calcium channel in Sprague-Dawley rat ... | 18754582 |
| Ileum | IC50 | = | 9340.0 | nM | 5.03 | Vasorelaxant activity in K+-depolarized guinea pig ileum longitudinal smooth mus... | 18754582 |
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 31158845 | 10.1038/s41586-019-1291-3 | ADMET | 64 |
| 22194678 | 10.1371/journal.pcbi.1002310 | Hepatotoxicity | 14 |
| - | 10.5281/zenodo.13943903 | ADMET | 13 |
| 18754582 | 10.1021/jm800151n | NON-PROTEIN TARGET | 4 |
| 34547896 | 10.1021/acs.jmedchem.1c00823 | Transthyretin | 4 |
| 37468498 | 10.1038/s41467-023-40064-9 | Nuclear receptor subfamily 1 group I member 2 | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | Gamma-aminobutyric acid receptor subunit alpha-1/alpha-2/beta-2/gamma-2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Muscarinic acetylcholine receptor M2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 2B | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Cannabinoid receptor 1 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 1A | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Progesterone receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 2A | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Peroxisome proliferator-activated receptor gamma | 2 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 2 |
| 26948801 | 10.1016/j.drudis.2016.02.015 | Homo sapiens | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-1A adrenergic receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Androgen receptor | 2 |
| 38318365 | 10.1016/j.isci.2024.108907 | Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-2A adrenergic receptor | 2 |
Data from ChEMBL 36 via Core Engine